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Methods: The purpose of this study was to investigate the effect of substitution between unbranded generics on persistence and adherence to
therapy in two Italian Local Health Units (ASL) in real-world clinical practice in 5 therapeutic areas using tracing drugs. Substitution of
generic drugs is any change in the name of the manufacturer of the generic drug. The therapeutic areas were: diabetes (metformin);
hypertension (amlodipine); dyslipidemia (simvastatin); psychiatry (sertraline); cardiology (propafenone); osteoporosis (alendronate). The
retrospective analysis was carried out on the administrative databases of two Local Healthcare Units (ASL e Azienda sanitaria locale
Bergamo (BG) and Pavia (PV)) in the Lombardy Region of Italy. The correlation between persistence and adherence with the different
cohorts of generic substitution frequency within each therapeutic area was then calculated.
Results: According to the inclusion criteria, 23,773 patients were evaluated. Patients were observed for a period of 36months starting from the first
drug delivery (index date). The median age of the overall population was above 61 years in all therapeutic areas. The generic drug substitution
occurred in61.5%ofpatients (BG:57.6%andPV:65.4%respectively);Hypertensionwas the therapeutic areawith the highest percentageofpatients
with substitutions. Patients’ adherence, evaluated by theMedical PossessionRate (MPR) andpersistence to the treatment decreaseswith the increase
in the frequency of generic substitutions. This observation was confirmed by a statistically significant negative correlation (p-value of <0.001)
between the adherence and persistence and the number of generic substitutions in each therapeutic area and Local Healthcare Units (ASL).
Discussion: Adherence is one of the pillars of the patient’s health management in the control and prevention of progression of the disease.
Several factors, such as ageing, comorbidities, and polypharmacy, may affect adherence and influence the outcome of treatments. These
results are in line with studies supporting the possibility that the change of package appearance each time a new prescription is dispensed
may create confusion and ultimately reduce patients’ adherence. Clinicians and decision makers should consider the impact of frequent
generic substitutions on persistence and adherence, which may influence efficacy and/or safety.
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2 G.L. Colombo et al. / Atherosclerosis Supplements 21 (2016) 1e81. Introduction generic substitution of antiepileptics (lamotrigine and top-Once the period of ‘exclusivity’ on a reference medicine
expires, it is possible to apply for marketing of a generic
version of that medicine [1]. By definition, a generic
product is considered interchangeable with the innovator
brand product when it demonstrates the same qualitative
and quantitative composition in active substances, the same
pharmaceutical form and bioequivalence with the reference
product after a single dose [2]. In Italy in 2014, the use of
generics represented 51.1% of the National Health Service
expenditure with an increase of þ6.6% with respect to 2013
and 70.4% of the total DDD with an increase of þ11.9%
over 2013. The percentage of the national expenditure for
bioequivalent generics (off-patent generic drugs, excluding
the off-patent originator) represented 28.8% of the total
expenditure for out-of-patent drugs [3].
Eventhough the use of generics is important to reduce
healthcare expenditure, there is a concern it may affect the
attitude of patients in following the prescribed indications,
which are not directly related to bioequivalence.
A specific reason for attention was raised on the effect of
generic substitution (i.e., switches between brand names
and generics, and switches between generics), which is
believed to affect medication safety and to create insecurity
in patients taking multiple drugs by the changes in the
appearance of their drugs. As a consequence, patients may
make mistakes or double-medicate, leading in turn to
increased drug non-adherence, therapeutic failure, unnec-
essary complications, disability and increased adverse
events even very serious ones. A survey conducted on
behalf of the Swedish government in 2004 concluded that
one-third of all patients feel worried when their drug is
substituted and one-third find it confusing when the names
change on their prescribed medication [4]. The possibility
that variation in packaging and pill appearance may affect
adherence is also a reason of concern.
Treatment adherence is a well-known predictor of clin-
ical outcome. Several factors, such as ageing, comorbidities
and polypharmacy, may in turn affect adherence and
influence the outcome of treatments [5e10]. Trotta et al.
[11] showed that the switching of generic drugs defined as
dispensing of two different products of the same substance
in a series of two prescriptions in the diabetes setting does
not influence patients’ adherence. Similarly, in the cardio-
vascular setting and in postmenopausal women with oste-
oporosis, adherence is not influenced by the switch to
generic drugs for antihypertensive agents and alendronate
[12e15]. In contrast, a study of the association between
generic substitution and persistence (number of days on
treatment) with oral bisphosphonates showed reduced
persistence [16].
In specific settings such as those involving psychiatric
and neurological conditions, the effects of generic substi-
tution are still unclear. In particular, two studies by Hartung
et al. [17] and Duh et al. [18] investigated the effect ofiramate) on a clinical outcome (i.e. the rate of hospitali-
zation) and showed opposite findings.
An Italian retrospective study [19] based on real-world
data on the effect of substitutions between branded vs
generic drugs in several pathologies showed that compli-
ance and persistence supported the use of generic drugs in
all therapeutic areas and the results were statistically
significant in the metformin, amlodipine, simvastatin, and
sertraline groups.
Until now, research has mostly focused on one shift from
a manufacturer’s specific drug to a generic drug [12,13,20];
only one study by Olesen et al. [5], assessing treatment
adherence among generic drug switches, found that
dispensing multiple generic drugs to elderly home living,
relatively healthy patients with polypharmacy did not
reduce adherence to long-term drug treatment and that
there seems to be no obvious reason for abolishing generic
substitutes, or constraining the appearance of tablets
(shape, size and color) and packages. In the same settings
and using the same tracing drugs as Colombo et al. [19],
this retrospective study aims specifically at quantifying the
frequency of substitution among generics, and to verify
whether switching between different generic products of
the same substance affects adherence and persistence of
use.
2. Materials and methods
The purpose of this study was to compare differences in
adherence and persistence of use of specific drugs in
subgroups of patients based on the frequency of switch
between unbranded generic drugs in real-world clinical
practice in 5 therapeutic areas using tracing drugs.
The 5 therapeutic areas were diabetes, hypertension,
dyslipidemia, psychiatry and osteoporosis with metformin,
amlodipine, simvastatin, sertraline and alendronate as
tracing drugs. The retrospective analysis was carried out by
using the administrative databases of two Local Healthcare
Units (ASL e Azienda sanitaria locale) in the Lombardy
Region of Italy and, specifically, Pavia and Bergamo. The
following administrative databases were used: flow of drugs
from pharmacies in the area, database of patients’ demo-
graphics and the death registry.2.1. Study populationAll patients who received at least one delivered
prescription of one of the generic study drugs in the above
mentioned areas between 01 January 2009 and 31
December 2010 were included in the analysis. The date of
first drug delivery was considered as the index date. In
order to consider only new patients, a 12-month wash-out
period before index date was applied during which
patients did not have a delivered prescription of the tracing
drugs. Patients were observed for a period of 36 months
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only one prescription of the tracing drugs (sporadic
patients) were excluded from the analysis. Cohorts were
defined in order to avoid any bias induced by the presence
of multiple diseases, which may have a strong impact on
the variability of the primary objectives. An additional
inclusion criterion for the psychiatry cohort was the use of
sertraline medication strengths of 50 mg or 100 mg only, in
order to exclude patients with anxiety. In the osteoporosis
cohort, all patients who had received systemic corticoste-
roid therapy during the 2 months preceding the index date
were excluded.2.2. Therapeutic areasThe therapeutic areas and tracing generic drugs selected
and the relevant Anatomical Therapeutic Chemical Clas-
sification System were defined as follows: diabetes: met-
formin e A10BA02, hypertension: amlodipine e C08CA0,
dyslipidemia: simvastatin e C10AA01, psychiatry: sertra-
line e N06AB06, osteoporosis: alendronate e M05BA04.
The list of off-patent drugs, both originator and generic,
marketed in Italy is regularly updated by the Italian
Medicine agency [21]. Off-patent medicines are classified
as branded and unbranded. Branded products are defined as
medicines sold under a proprietary name, whereas
unbranded generics are sold under the international non-
proprietary name (i.e., the name of the substance). Only
unbranded generics were considered.2.3. Outcome indicatorsThe primary objective was to define the percentage of
patients with at least one substitution of generic drugs
within each therapeutic area. Substitution of generic drugs
is intended as any change in the name of the manufacturer
of the generic drug, for example for simvastatin: Simvas-
tatin “Hexal”, Simvastatin “Ratiopharm”, Simvastatin
“Teva”, Simvastatin “Doc Generici”, etc.
Percentage of patients with substitutions was calculated
by using as numerator the number of patients with at least
one substitution in the whole observation period and as
denominator the total number of patients included in the
study. The percentage of substitution among generics was
calculated as follows:ðNumber of times a generic drug was substituted with another generic drug with the same active principleÞ=
ðTotal number of prescriptions 1Þ:Additional objectives of this study included the defini-
tion of the patient population within each therapeutic area
and within each area, the identification of theirdemographic characteristics and the assessment of the
distribution of patients based on frequency of substitutions.
Persistence was the period of therapy-days between the
first dispensing and therapy interruption. It was calculated
as a continuous variable in terms of number of therapy-days
for which the therapy is available without interruption. The
total number of therapy days was analyzed by means of the
Defined Daily Dose (DDD) [22]. Intervals, called
‘‘maximum allowed gaps’’ (GAP), were defined according
to the type of therapy, the maximum time intervals between
two deliveries were defined in order to consider therapy
interruptions. The gap was defined as 90 days for diabetes,
hypertension, and dyslipidaemia, 60 days for osteoporosis,
and 30 days for psychiatry. Therapy interruption also
included switch to the originator (branded) or to different
molecules to treat the disease. Mortality data from the death
registry was considered in the analysis in order to differ-
entiate gaps from interruptions due to death.
Adherence to therapy (i.e. treatment compliance) was
calculated by means of the Medical Possession Ratio
(MPR). MPR was defined as the ratio between the number
of packs in the period of persistence multiplied by the
number of DDDs per pack, divided by the total days until
change of therapy (i.e., persistence). The correlation
between persistence and adherence with the different
cohorts of substitution frequency within each therapeutic
area was then calculated. In each ASL, the same analytical
procedures of extraction were used and all analyses was
performed with SAS 9.4.3. Results3.1. Characteristics of the patientsAccording to the inclusion criteria, 13,202 patients were
included from the ASL in Bergamo (BG) and 10,571 from
the ASL in Pavia (PV). The patient population studied per
therapeutic area were 8026 with dyslipidemia (4542 in the
ASL in Bergamo (BG) and 3484 in Pavia (PV)), 6218 with
hypertension (2972 in the ASL in Bergamo (BG) and 3246
in Pavia (PV)), 6117 patients with diabetes (3840 in BG
and 2277 in PV), 2407 with psychiatric diseases (1287 in
the ASL in Bergamo (BG) and 1120 in Pavia (PV)), 1005
with osteoporosis (561 in the ASL in Bergamo (BG) and
444 in Pavia (PV)).The median age in the overall population was above 61
years of age in all therapeutic areas. The largest group
being that aged 60e80 years. The mean age in diabetes was
Table 2
mean frequency of substitutions by therapeutic areas and by ASL.
Therapeutic area ASL Bergamo ASL Pavia
N Mean SD N Mean SD
Diabetes 3840 0.17 0.24 2277 0.19 0.25
Dyslipidemia 4542 0.26 0.31 3484 0.29 0.32
Hypertension 2972 0.27 0.31 3246 0.30 0.31
Osteoporosis 561 0.22 0.29 444 0.25 0.30
Psychiatry 1287 0.33 0.38 1120 0.33 0.36
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Bergamo (BG) and Pavia (PV), respectively, 65.72
(11.18) and 67.12 (11.24) in dyslipidemia, 67.70
(13.24) and 68.44 (13.10) in hypertension, 59.35
(18.54) and 62.34 (18.58) in psychiatry, and 71.16
(10.27) to 73.20 (10.06) in osteoporosis.
Regarding gender distribution, females were prevalent in
the psychiatric treatment (62.1 and 63% of patients in BG
and PV, respectively) and in the osteoporosis groups
(91.4% and 85.6% of patients were female in BG and PV,
respectively).3.2. Persistence, adherence (compliance to therapy)
and outcome indicatorsOn average, at least one generic drug substitution was
experienced by 57.6% of patients in the ASL in BG and
65.4% in the ASL in PV (Table 1).
More patients in the PV ASL substituted generic drugs
than in the BG ASL. Hypertension was the therapeutic area
with the highest percentage of patients with substitutions
(64.23% of patients substituting in BG and 69.32% in PV),
followed by dyslipidemia (58.01 and 66.88% of patients in
BG and PV respectively), psychiatry (55.56 and 63.84% in
BG and PV respectively), diabetes (54.32 and 60.34% in
BG and PV respectively), and osteoporosis (51.34 and
57.88% in BG and PV respectively). The mean percentage
of substitutions by therapeutic area and by ASL is reported
in Table 2.
In the psychiatric therapeutic area it was observed the
highest percentage of substitution (33% in both ASLs) that
means there was a generic drug substitution out of three
prescriptions. Diabetes is the therapeutic area with the least
percentage of substitution (17% in BG and 19% in PV)
with a generic drug substitution out of around five
prescriptions. When patients with substitutions were cate-
gorized in substitution frequency classes of 15 percentage
points, it appears that those with a lower range of had the
longest persistence in all therapeutic areas and in both
ASLs in comparison with patients with a higher range of
substitutions, highlighting that the persistence of treatmentTable 1
Number and percentage of patients with no substitution or with at least 1 substitu
by ASL.
Therapeutic area ASL Bergamo
No substitution At least one substitution
N % N %
Diabetes 1754 45.68 2086 54.32
Dyslipidemia 1907 41.99 2635 58.01
Hypertension 1063 35.77 1909 64.23
Osteoporosis 273 48.66 288 51.34
Psychiatry 572 44.44 715 55.56
Total 5569 42.18 7633 57.82decreases with the increase in the frequency of substitutions
(Table 3).
In the BG ASL, patients with a range of substitutions
between 1 and 15% had a persistence of treatment that
ranges from 1201 days for hypertension to 815 days for
psychiatry whereas patients with a range of substitutions
over 60% had a persistence of treatment that ranges from
401 days for hypertension to 197 days for psychiatry.
Similarly, in the PV ASL, patients with a range of substi-
tutions between 1 and 15% had a persistence of treatment
that ranges from 988 days for hypertension and diabetes to
817 days for osteoporosis whereas patients with a range of
substitutions over 60% had a persistence of treatment that
ranges from 448 days for hypertension to 247 days for
psychiatry. The more frequent the substitution, the shorter
the persistence in therapy. This observation has also been
confirmed by a statistically significant negative correlation
(ranges from 0.45 for diabetes in the BG ASL to 0.68
for psychiatry in the BG ASL; p-value of <0.001) between
the persistence and the number of substitutions in each
therapeutic area and ASL (Table 5).
Compliance, similarly to persistence, showed that the
adherence to the treatment decreases as the frequency of
substitutions increases (Table 4).
Adherence of diabetic patients showed a decreasing
trend from a mean of 68%e50% in BG, and from 84% to
60% in PV starting from the substitutions frequency range
1e15% to substitutions frequency range of 60%.of the
observation period. Mean adherence in dyslipidemia
showed an even more pronounced decreasing trend asso-
ciated with the increase in the frequency substitution, i.e.
from an adherence of 66%e46% in BG and from antion of generic drugs during the observation period by therapeutic area and
ASL Pavia
No substitution At least one substitution
N % N %
903 39.66 1374 60.34
1154 33.12 2330 66.88
996 30.68 2250 69.32
187 42.12 257 57.88
405 36.16 715 63.84
3645 34.48 6926 65.52
Table 4
Adherence to treatment stratified by generic substitution class, therapeutic area and by ASL.
Therapeutic area Substitution frequency classes MPR
ASL Bergamo ASL Pavia
N Mean SD N Mean SD
Diabetes Range (1%e15%) 605 0.68 0.23 457 0.84 0.21
Range (15%e30%) 595 0.65 0.25 359 0.76 0.25
Range (30%e45%) 413 0.64 0.25 257 0.71 0.27
Range (45%e60%) 232 0.61 0.27 117 0.68 0.28
Range (60%) 241 0.50 0.28 184 0.60 0.30
Dyslipidemia Range (1%e15%) 430 0.66 0.20 410 0.83 0.22
Range (15%e30%) 586 0.59 0.20 561 0.77 0.25
Range (30%e45%) 477 0.58 0.21 465 0.67 0.28
Range (45%e60%) 410 0.52 0.22 251 0.53 0.22
Range (60%) 732 0.46 0.24 643 0.49 0.24
Hypertension Range (1%e15%) 369 0.96 0.09 384 0.98 0.06
Range (15%e30%) 429 0.93 0.14 537 0.96 0.11
Range (30%e45%) 364 0.91 0.15 406 0.94 0.13
Range (45%e60%) 306 0.90 0.16 325 0.91 0.15
Range (60%) 441 0.81 0.24 598 0.85 0.21
Osteoporosis Range (1%e15%) 36 0.92 0.09 37 0.98 0.05
Range (15%e30%) 77 0.86 0.15 66 0.93 0.11
Range (30%e45%) 63 0.88 0.12 48 0.84 0.21
Range (45%e60%) 48 0.77 0.21 43 0.81 0.22
Range (60%) 64 0.71 0.27 63 0.71 0.26
Psychiatry Range (1%e15%) 56 0.97 0.09 81 0.98 0.07
Range (15%e30%) 106 0.93 0.12 139 0.96 0.12
Range (30%e45%) 96 0.89 0.18 130 0.91 0.16
Range (45%e60%) 131 0.80 0.25 85 0.82 0.24
Range (60%) 326 0.78 0.25 280 0.78 0.28
Table 3
Persistence of treatment stratified by generic substitution class, therapeutic area and by ASL.
Therapeutic area Substitution frequency classes Persistence (days)
ASL Bergamo ASL Pavia
N Mean SD N Mean SD
Diabetes Range (1%e15%) 605 984.64 212.29 457 988.50 263.98
Range (15%e30%) 595 851.60 316.78 359 867.90 344.50
Range (30%e45%) 413 782.51 359.58 257 694.99 398.36
Range (45%e60%) 232 605.50 413.74 117 747.40 401.98
Range (60%) 241 310.51 315.76 184 352.60 355.20
Dyslipidemia Range (1%e15%) 430 980.66 209.82 410 890.48 319.53
Range (15%e30%) 586 820.88 311.35 561 758.15 376.38
Range (30%e45%) 477 750.85 348.65 465 615.14 400.90
Range (45%e60%) 410 585.23 401.08 251 595.97 412.08
Range (60%) 732 371.79 357.76 643 407.06 374.70
Hypertension Range (1%e15%) 369 1021.12 196.89 384 988.09 302.92
Range (15%e30%) 429 882.48 314.32 537 817.60 366.28
Range (30%e45%) 364 782.72 364.22 406 710.08 396.75
Range (45%e60%) 306 615.38 406.90 325 696.23 405.76
Range (60%) 441 401.58 374.06 598 448.23 381.11
Osteoporosis Range (1%e15%) 36 969.28 218.82 37 817.51 350.82
Range (15%e30%) 77 710.52 345.12 66 734.36 359.42
Range (30%e45%) 63 710.76 353.06 48 515.17 410.43
Range (45%e60%) 48 503.00 377.09 43 514.81 391.46
Range (60%) 64 367.63 343.12 63 375.24 331.00
Psychiatry Range (1%e15%) 56 815.07 291.03 81 841.30 354.41
Range (15%e30%) 106 566.19 326.88 139 660.93 399.34
Range (30%e45%) 96 481.77 360.16 130 457.92 320.43
Range (45%e60%) 131 320.36 280.15 85 359.11 338.91
Range (60%) 326 197.78 171.33 280 247.45 252.37
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Table 5
Correlation between persistence and adherence to treatment and generic substitution stratified therapeutic area and by ASL.
Therapeutic area Persistence MPR
Bergamo Pavia Bergamo Pavia
Pearson corr. Coeff. p-value Pearson corr. Coeff. p-value Pearson corr. Coeff. p-value Pearson corr. Coeff. p-value
Diabetes 0.45005 <0.0001 0.47038 <0.0001 0.17708 <0.0001 0.30642 <0.0001
Dyslipidemia 0.56764 <0.0001 0.48464 <0.0001 0.32662 <0.0001 0.47813 <0.0001
Hypertension 0.53508 <0.0001 0.49124 <0.0001 0.27340 <0.0001 0.38135 <0.0001
Osteoporosis 0.51589 <0.0001 0.46460 <0.0001 0.30139 <0.0001 0.50583 <0.0001
Psychiatry 0.68829 <0.0001 0.64439 <0.0001 0.30457 <0.0001 0.40548 <0.0001
6 G.L. Colombo et al. / Atherosclerosis Supplements 21 (2016) 1e8adherence of 83%e49% in PV in the substitutions
frequency range 1e15% and 60%, respectively. In hyper-
tension, adherence to therapy was high: 96% in BG and
98% in PV the substitutions frequency range 1e15%, to
81% in BG and 85% in PV in the substitutions frequency
range of 60%. Similarly, in osteoporosis and in psychi-
atry, adherence to treatment was high with 92% and 97% in
BG and 98% in PV in the lowest substitution frequency
range (1e15%) to 71% and 78% in BG and PV for in the
highest substitutions frequency range (60%). In general,
those supplied with more frequent substitution drugs were
significantly less likely to be adherent than patients with
fewer substitutions.
Furthermore, a statistically significant negative correla-
tion (ranges from 0.17 for diabetes in the BG ASL to
0.5 for osteoporosis in the PV ASL; p-value of <0.001)
between the adherence and the number of substitutions in
each therapeutic area and ASL (Table 5) was found.
4. Discussion
The present study aimed at investigating the effect of
substitution between generics on persistence and adherence
to therapy in two Italian Local Health Units. Our results
indicate that both adherence and persistence decrease
significantly with the increasing frequency of substitutions.
In the overall population, independently of the therapeutic
area investigated and the ASL of origin, persistence
significantly dropped from a range of 800e1000 days to
a range of 197e448 days from substitution frequency class
1e15% to frequency class 60% (p < 0.001) and average
adherence varied between 45% and 92%, with the highest
rate in the hypertensive, osteoporotic and psychiatric
patients.
These results are in line with studies to support the
possibility that the change in package appearance each time
a new prescription is dispensed may create confusion and
ultimately reduce patients’ adherence [23,24]. Kesselheim
et al. [25] showed that changes in pill colors and shapes
increased the risk of non-adherence among epileptic
patients. Substituting patented originators with generic
alternatives, as well as switching between different
generics, may carry a risk for patients’ outcome, especially
in case of chronic diseases such as diabetes, dyslipidemia,hypertension etc. since pharmacological treatment include
different substances and different packaging (of all
branded/generic products) of the same substance.
Clinical literature supports the full replaceability of off-
patent branded with off-patent generic drugs in cardiovas-
cular diseases [26e29], and other chronic diseases such as
diabetes [5,6,11] and osteoporosis [14,16,30]. No associa-
tion between generic substitution and non-adherence was
found in these studies. Trotta et al. [11] showed that, the
substitution between branded and unbranded products (as
well as between generics) of the same substance, did not
negatively affect adherence in elderly patients treated with
antidiabetics.
In contrast, in the neurology and psychology field data is
more conflicting and depends on the type of disease treated,
such as epilepsy [17,31], Parkinson disease [32] or
depression [33]. In this latter disease, older patients were
more likely to be adherent to therapy. Also, the prior use of
certain medications could have affected adherence and
persistence with antidepressant therapy. With respect to the
use of bisphosphonates, a study of the association between
generic substitution and persistence (number of days on
treatment) showed reduced persistence [16]. In our world of
evidence-based medicine, health management improve-
ment focuses mostly on implementing appropriateness of
use as derived from large scale clinical trials as indicator of
the good quality of care. Clinical outcomes are affected not
only by how well patients take their medications but also by
how long they take them. Thus, compliance and persistence
should be measured separately from clinical outcome to
characterise “medication-taking” behavior comprehen-
sively. Addressing both compliance and persistence
provides a richer understanding of “medication-taking”
behavior [34].
The WHO had identified medication persistence as
a critical component of successful pharmacotherapy [1].
Adherence, in chronic diseases such as diabetes, cardio-
vascular diseases, osteoporosis or psychiatric diseases is
a fundamental aspect of the patient’s health management.
Preventive measures in cardiovascular diseases, diabetes
and psychiatrics show that effects can be deferred in time
and require that patients comply with the prescribed treat-
ment continuously and at the effective daily doses. Lack of
persistence in and of adherence to treatment is therefore
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In Sweden, automatic generic substitution of alendronate
products and medication persistence were studied retro-
spectively between 2006 and 2009. During this period the
number and rate of substitution between alendronate
products increased, while persistence decreased. An earlier
study [19] in a large Italian prescription area (3,847,000
inhabitants) from 5 Local Health Units, patients with
metabolic, cardiovascular, psychiatric, and osteoporotic
disease were retrospectively surveyed to assess any differ-
ences in compliance and persistence with treatment,
mortality and more/less use of other health resources
between off-patent generic and off-patent branded drugs.
In the Italian Region of Lombardy [19], adherence and
persistence were in favor of generic drugs in all therapeutic
areas investigated and statistically significant in the met-
formin, amlodipine, simvastatin, alendronate and sertraline
groups. The clinical outcomes (hospitalizations, mortality,
and other health costs) show no statistically significant
differences between off-patent generic vs. off-patent brand
medicines. From the socio-economic point of view, off-
patent generic medicines appear to be a very useful tool,
obtaining the same therapeutic effectiveness by improving
the economic impact on patients and, in the end, on the
National Health Service (NHS). Furthermore, generic drugs
with their low purchase price and the complete or almost
complete reimbursement by the NHS, may favor better
adherence to treatment.
The unfavorable effects of lack of persistence and
adherence in cardiac diseases were demonstrated by clin-
ical studies such as WOSCOPS [35] and CHARM [36]
where non-compliant patients not only failed to reach
their lipid and glucose goals, but also had an increase in
hospitalisation and fatal and non-fatal cardiovascular
events, which affected the National Health costs. In a recent
meta-analysis, the relative risk of an unfavorable clinical
outcome for non-compliant patients to hypolipidemic
treatment was equal to 2.8, anti-hypertensive treatment was
equal to 2.8, and anti-ischemic treatment was equal to 1.5
[37]. Of note, adherence and persistence were estimated
based on the real consumption of the medications as
prescribed by active principle. The quality and accuracy of
the regional and local health units registry is high and the
frequency of missing values is very low. Together with
these important observations, we need, however, to
consider the limitations of this retrospective study. When
using administrative claims database, there is potential for
selection bias, miscoding of information and consequent
biases in estimation. The collected data taken directly from
invoicing by pharmacies gives a real estimate of prescribed
and dispensed drugs, but not of the actual use of the drugs
by patients. They also lack clinical data since they are
created for accounting purposes, in fact data on the
patients’ lifestyle, on symptoms and diagnoses, and on
intermediate outcome indicators (vital signs or biochemical
levels) are not available. It is therefore, not possible tostudy the reasons linking frequent switches among generics
to persistence and adherence. The lack of detailed clinical
data on the severity of the disease, illness history, patient
responses to medication including adverse events and the
lack of detailed social demographic data on education,
employment status, income family environment, and
patient’s and physician’s belief and preference were not
collected. There are many other factors associated with
frequency of substitution of generics that may influence
patient’s propensity to discontinue treatment, such as
confusion and anxiety due to different names, the appear-
ance of generic products and general skepticism towards
medication substitution.
5. Conclusions
Substitution among generic drugs with different formu-
lations and appearance is feasible. The higher the frequency
of substitutions, the shorter the persistence and adherence
with therapy. The impact of frequent substitutions on
persistence and adherence, which may influence efficacy
and/or safety should therefore be monitored and if possible
avoided. Given the clinical and economic benefits of better
adherence and persistence with therapy, targeting inter-
ventions to patients who are at high risk for non-adherence
and early discontinuation, should be an important part of
medication therapy in chronic diseases [2,33,34,38].
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